NCRI Lymphoma and Radiotherapy Group:

Stanford V vs. ABVD Trial

* This trial has now closed*

RANDOMISED PHASE III STUDY OF THE STANFORD V REGIMEN, COMPARED WITH ABVD FOR THE TREATMENT OF ADVANCED HODGKIN’S DISEASE

To compare in a multicentre, randomised trial Stanford V with ABVD in patients with advanced (Stages IIB – IV) Hodgkin’s Disease using relapse free survival as the primary endpoint. Eligible patients will be randomised to receive either Stanford V chemotherapy, for 12 weeks, or 6 to 8 cycles of ABVD. All patients achieving a partial remission (PR) to chemotherapy will receive involved field radiotherapy (IFRT). Patients who receive Stanford V chemotherapy and achieve a complete remission (CR) to chemotherapy will receive IFRT if they had initial bulky mediastinal disease, initial nodal masses measuring ³5cm in diameter, or initial splenic disease. Patients who receive ABVD and achieve a CR will not receive radiotherapy. The radiotherapy regimen will be the subject of a formal quality assurance programme.